tirzepatide shortage update FDA Resolves Shortage: Impact on Supply Chain Lilly, Novo Fight Weight Loss

A small 2024 pilot study examining tirzepatide (a dual GIP/GLP-1 agonist) showed similar trends, with participants reporting lower withdrawal symptom severity during quit attempts

Additionally, researchers noted several Phase 1.5 pipeline candidates in a recent review

February 25,2026- Shrewsbury Massachusetts pharmaceutical company in hot water for fake Ozempic allegations Novo Nordisk has filed an ozempic lawsuit against a local Shrewsbury Massachusetts pharmaceutical company alleging that the owner of the company wrongfully and incorrectly marketed a non authentic version of Wegovy and Ozempic

In healthy human volunteers, a diet with 30% kcal from protein (40% carbohydrates, 30% fat) causes greater GLP-1 secretion than a diet with 10% kcal protein (60% carbohydrates, 30% fat) [308]

The cash-pay structure simplifies billing but means commercial GLP-1 coverage doesnt apply through the platforms